Back to today’s briefing

Story perspectives

BridgeBio Merges for $450M to Target Cancer Mutations

2/28/2025

50 7

Summary

Story summary

BridgeBio Oncology Therapeutics is set to make waves in the stock market by merging with Helix Acquisition Corp. II, a move that will secure over $450 million for advancing three promising drug candidates aimed at KRAS mutations in cancer. Anticipated to finalize in Q3 2023, the new entity will debut on Nasdaq under the ticker "BBOT."

1 of 1

Story summary

BridgeBio Oncology Therapeutics is set to make waves in the stock market by merging with Helix Acquisition Corp. II, a move that will secure over $450 million for advancing three promising drug candidates aimed at KRAS mutations in cancer. Anticipated to finalize in Q3 2023, the new entity will debut on Nasdaq under the ticker "BBOT."